In this longitudinal, open‑label clinical trial, 20 participants with severe, treatment‑resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, one week apart) in a supportive therapeutic setting. Depressive symptom severity was assessed from baseline through six months post‑treatment, primarily using the self‑rated QIDS‑SR16 scale. Results showed rapid and significant reductions in depressive scores by one week post‑treatment, with large effect sizes maintained at three and six months; a substantial proportion of participants met criteria for clinical response and remission during follow‑up. The intervention was well tolerated overall, with no serious adverse events reported, reinforcing the potential of psilocybin‑assisted therapy as a feasible and impactful option for treatment‑resistant depression.
From Psychopharmacology, Springer Nature (Open Access)